JOHNSON & JOHNSON | 67,45 Euro | -0,16 -0,24 % | |
| WKN: 853260 ISIN: US4781601046 Ticker-Symbol: JNJ | Frankfurt | 24.05.13 | 17:48 Uhr |
Branche KonsumgüterAktienmarkt DJ IndustrialS&P 100 S&P 500 |
|
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 24.05. | Johnson & Johnson plans to submit over 10 new drugs for regulatory approval by 2017 | 4 | Pharma Bus Review | |
| 24.05. | Johnson & Johnson Pakistan to wind up operations | - | Pharma Bus Review | |
| 23.05. | Follow The 'Smart Money' And Buy Johnson & Johnson In The Next Pullback | 1 | Seeking Alpha | |
| 23.05. | 3rd UPDATE: J&J to Submit More Than 10 New Drug Applications by 2017 | - | Euroinvestor | |
| 23.05. | 22.9% Return Seen to Date on SmarTrend Johnson & Johnson Call | 1 | SmarTrend | |
| 23.05. | UPDATE 2-New J&J anti-depressant related to "Special K" party drug | - | Reuters.com | |
| 23.05. | 2nd UPDATE: J&J to Submit Over 10 New Drug Applications by 2017 | - | Euroinvestor | |
| 23.05. | UPDATE: J&J To Submit Over 10 New Drug Applications By 2017 | 1 | Euroinvestor | |
| 23.05. | New Stock Coverage: Can Johnson & Johnson Be Market's Band-Aid? | 2 | Minyanville | |
| 23.05. | Johnson & Johnson to Submit 10 New Product Filings by 2017 | 1 | Euroinvestor | |
| 23.05. | Johnson & Johnson plans on more than 10 drugs filed by 2017 | 2 | Reuters.com | |
| 23.05. | J&J's Janssen Poised to Continue Driving Growth, Outlines 10+ Potential New Product Filings by 2017 | 1 | Benzinga.com | |
| 23.05. | J&J Sees 10 Products Submitted For Approval by 2017 | - | Bloomberg | |
| 23.05. | Johnson & Johnson Pharmaceuticals Segment Poised to Continue Driving Growth with More than 10 Potential New Product Filings by 2017 | 69 | PR Newswire | |
| NEW BRUNSWICK, N.J., May 23, 2013 /PRNewswire/ -- At a meeting today with industry analysts, senior leaders from the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced they... Mehr lesen zu: Johnson & Johnson Pharmaceuticals Segment Poised to Continue Driving Growth with More than 10 Potential New Product Filings by 2017 | ||||
| 23.05. | Credit Suisse nimmt die Bewertung für Johnson & Johnson mit Underperform wieder auf. | 89 | BörseGo | |
| Credit Suisse nimmt die Bewertung für Johnson & Johnson mit Underperform wieder auf.
(© BörseGo AG 2013 - Autor: Thomas Gansneder, Redakteur) Mehr lesen zu: Credit Suisse nimmt die Bewertung für Johnson & Johnson mit Underperform wieder auf. | ||||
| 23.05. | Johnson & Johnson: At The Crossroads - Part IV - One Road To Higher Profit Growth Rates | - | Seeking Alpha | |
| 22.05. | XETR DIVIDEND INFORMATION - 23.05.2013 - 1 | 623 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 22.05.2013 CUM DIVIDENDE UND AM 23.05.2013
EX DIVIDENDE GEHANDELT.
THE PRE-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 22.05.2013. THE
EX-DIVIDEND DAY WILL BE 23.05.2013.
... Mehr lesen zu: XETR DIVIDEND INFORMATION - 23.05.2013 - 1 | ||||
| 22.05. | XFRA DIVIDEND INFORMATION - 23.05.2013 - 1 | 88 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 22.05.2013 CUM DIVIDENDE UND AM 23.05.2013
EX DIVIDENDE GEHANDELT.
THE PRE-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 22.05.2013. THE
EX-DIVIDEND DAY WILL BE 23.05.2013.
... Mehr lesen zu: XFRA DIVIDEND INFORMATION - 23.05.2013 - 1 | ||||
| 21.05. | JNJ's Simponi Label Expanded | 4 | Zacks | |
| 21.05. | J&J's Janssen Announces Primary Efficacy, Safety Findings from Phase 3 Study of Simeprevir Once Daily | 2 | Benzinga.com | |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| PROCTER & GAMBLE | 63,27 | +4,12 % | S&P Capital IQ belässt Procter & Gamble auf 'Hold' |
| UNILEVER | 32,484 | -0,21 % | Citigroup belässt Unilever NV auf 'Neutral' - Ziel 33,50 Euro |
| COLGATE-PALMOLIVE | 46,90 | -0,96 % | Colgate-Palmolive Files A Patent For A Chemical-Infused Toothbrush |
| 3M | 85,10 | 0 % | XETR DIVIDEND INFORMATION - 22.05.2013 - 1 |
| RECKITT BENCKISER | 56,61 | -0,14 % | Citigroup belässt Reckitt Benckiser auf 'Buy' - Ziel 5.450 Pence |
